Please note that following on from information provided to NICE by the company in January 2014, the appraisal of Masitinib for treating unresectable or metastatic gastrointestinal stromal tumours after treatment with imatinib [ID622] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 622 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | Alice Law |
| Project manager: | Jeremy Powell |
| Technical Lead: | Ahmed Elsada |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 January 2023 | Discontinued. Please note that following on from information provided to NICE by the company in January 2014, the appraisal of Masitinib for treating unresectable or metastatic gastrointestinal stromal tumours after treatment with imatinib [ID622] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 22 July 2014 | We are suspending this appraisal. This is because the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has decided not to approve masitinib for treating unresectable or metastatic gastrointestinal stromal tumours after treatment with imatinib. |
| 20 February 2014 | Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. |
For further information on our processes and methods, please see our CHTE processes and methods manual